Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Medicare, Leqembi and Alzheimer's
Leqembi's vial design could result in hundreds of millions in annual Medicare waste: study
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be unused and discarded, according to a new study published in JAMA Internal Medicine. That could result in $133 million to $336 million in waste per year for Medicare, the study found.
New Vial Size Could Save US Medicare Millions on Alzheimer's Breakthrough Drug Leqembi
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or lecanemab by simply introducing a new vial size that would reduce the amount of unused medication thrown away.
Big vials of Alzheimer's drug could cost Medicare $336M
Medicare could be throwing away as much as $336 million worth of a costly Alzheimer's drug each year because the size of vials is too big, UCLA researchers estimate. Why it matters: The findings, published Monday in JAMA Internal Medicine,
pharmaphorum
15h
Australia joins EU in turning down Alzheimer's drug Leqembi
Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
3d
on MSN
Changing Alzheimer's drug vial size might save big money for Medicare
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
2d
on MSN
Alzheimer's: Simple Drug Change Could Save Medicare Hundreds of Millions
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
ENDPOINTS NEWS
9h
Eisai to ask Australia to reconsider rejection of Alzheimer's drug Leqembi
Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...
pharmaphorum
14h
NICE backs first targeted therapy for ALK+ lung cancer
In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...
The American Journal of Managed Care
3d
Discarded Lecanemab Leads to Medicare Drug Waste of Up to $336 Million
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
U.S. News & World Report
3d
Change in Alzheimer's Drug Vial Size Could Be Big Money-Saver for Medicare
About 6% of
Leqembi
(lecanemab) is discarded because patients are frequently prescribed doses lower than the size of the
drug
’s single-use vials. This waste costs Medicare about $1,600 a patient ...
1d
Experts label TGA’s decision to not register Alzheimer’s drug ‘extremely disappointing’
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
1d
on MSN
More kids having seizures after ingesting medications, illicit drugs
The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in ...
Yahoo Finance
9h
Lilly Loses Around $14B This Week: How to Play LLY Stock
Lilly believes Kisunla can generate blockbuster sales. Kisunla is only the second
drug
on the market to treat Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Alzheimer's disease
Medicare
Feedback